Health and Healthcare
Amgen Earnings Point to More Froth in the Biotech Sector
Published:
Last Updated:
Product sales rose 12% compared with the first quarter of 2014, primarily on the sale of the company’s Enbrel, Prolia, Epogen, Sensipar and Xgeva products. Growth was the result of price and higher demand.
R&D expenses dropped by 14% and total operating expenses fell by 3% to $2.58 billion. Amgen’s operating margin rose to 50.2% from 42.7% in the same period a year ago.
In its guidance statement, Amgen raised the low end of its revenue estimate by $100 million to a new range of $20.9 million to $21.3 billion for the full fiscal year. The top end of the range was unchanged. The adjusted EPS range rose from $9.05 to $9.40 to a new range of $9.35 to $9.65.
Analysts had consensus second-quarter estimates of $2.36 for EPS and $5.29 billion for revenues. Full-year estimates called for EPS of $9.32 and revenues of $20.98.
The company’s CEO said:
With solid execution in the first quarter, Amgen achieved strong sales and earnings growth and demonstrated substantial progress in achieving our long-term objectives. Our continuing success in delivering results gives us the confidence to increase our full year outlook for earnings.
ALSO READ: 4 Biotech and Pharma Stocks Projected to Rise 50% to 100%
Amgen beat the consensus EPS estimate by 18%. That showing is likely to drive the biotech stocks to even greater heights. While Amgen cannot pump the entire sector all by itself, it is a bellwether for the biotechs and we can expect some new tops going forward.
Shares traded higher by more than 2% in the after-hours session Tuesday, at $172.00 in a 52-week range of $108.20 to $173.14. Thomson Reuters had a consensus price target on the stock of $176.84 before the results were announced.
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.